On September 11, 2026, AtaiBeckley Inc. completed its merger with Eli Lilly and Company via Albali Acquisition Corporation, becoming a wholly owned subsidiary of Parent. Each outstanding share of common stock was converted into $6.75 in cash plus one contingent value right (CVR). CVRs provide potential additional cash payments up to $2.50 per share based on clinical and regulatory milestones for VLS-01 and BPL-003 within specified timeframes. Equity awards were settled or cancelled accordingly, and the company's board of directors and executive officers resigned while new appointees from Parent assumed leadership roles. The company requested delisting from Nasdaq and intends to file Form 25 and Form 15 to terminate reporting obligations. AtaiBeckley Inc. operates in the biotechnology industry, focusing on psychedelic medicine development.

AtaiBeckley Inc. held a virtual special meeting of stockholders on September 8, 2026, to vote on the adoption of its Merger Agreement with Eli Lilly and Company. The merger proposal was approved by approximately 97.6% of votes cast, with 237,762,253 shares voting in favor against 5,033,755 opposed, representing about 65.6% of outstanding shares present or represented. Assuming satisfaction of closing conditions, the merger is expected to be consummated on September 11, 2026. AtaiBeckley Inc. operates in the biotechnology industry, focusing on the development of treatments for mental health disorders.

On July 15, 2026, AtaiBeckley Inc. entered into a definitive merger agreement to be acquired by Eli Lilly and Company. AtaiBeckley shareholders will receive $6.75 per share in cash plus one contingent value right (CVR) per share, which can provide up to an additional $2.50 per share based on clinical and regulatory milestones for BPL-003 and VLS-01. The transaction represents an aggregate upfront equity value of approximately $2.8 billion. The merger is subject to stockholder approval and regulatory clearances, with a termination fee of $104.3 million payable by AtaiBeckley under certain conditions. AtaiBeckley is a clinical-stage biopharmaceutical company developing therapeutics for mental health conditions.

AtaiBeckley Inc. held its annual meeting of stockholders on June 4, 2026, where the election of Class I directors and the first proposal to ratify Deloitte & Touche LLP as its independent registered public accounting firm were both approved. Approximately 366,916,896 shares of common stock were outstanding and entitled to vote, with 203,908,561 shares represented at the quorum.